Phase 4
N=58
Effects of Armodafinil on Cognition for Patients With Schizophrenia or Schizoaffective Disorder
Schizophrenia · Schizoaffective Disorder
Bottom Line
View on ClinicalTrials.gov: NCT00373672 ↗Enrolled (actual)
58
Serious AEs
0.0%
Results posted
Aug 2025
Primary outcome: Primary: Cognition Measured by AX-Continuous Performance Test (AX-CPT) D-prime Score — 2.7; 2.5; 2.3; 3.2 d prime score — p=<0.016
Study Design & Population
- Study type
- Interventional
- Phase
- Phase 4
- Interventions
- armodafinil (Nuvigil) (Drug); placebo (Drug)
- Age
- Adult, Older Adult · 18+ yrs
- Sex
- All
- Sponsor
- Northwestern University
- Primary completion
- Jan 2010
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Cognition Measured by AX-Continuous Performance Test (AX-CPT) D-prime Score |
2.7; 2.5; 2.3; 3.2 | <0.016 sig |
Summary
This is a six week, double blind,placebo controlled study for patients with schizophrenia or schizoaffective disorder treated with an atypical antipsychotic for at least two months. Subjects will be randomized to take armodafinil (Nuvigil) or placebo along with their current antipsychotic and tested at baseline and week 6 for differences in memory, attention and problem-solving ability. Changes in weight during the six week study will also be tracked.
Eligibility Criteria
Inclusion criteria
- Men and women age 18-65 years
- Patients with Diagnostic and Statistical Manual (DSM-IV) defined schizophrenia or schizoaffective disorder
- Treated with any atypical antipsychotic for at least 2 months
- Patients with documented weight gain > 7% with current antipsychotic medication
- Able to provide written consent
Exclusion criteria
- Women who are pregnant or nursing. Female participants must have a negative urine pregnancy test at screening.
- DSM-IV defined substance or alcohol dependence within the 2 months preceding the start of the trial
- Treatment with a monoamine oxidase inhibitor (e.g., tranylcypromine, phenelzine, isocarboxazid) within 2 weeks of starting the trial
- Patients considered at high risk for suicide or violence
- Patients with history of or symptoms on systems review consistent with clinically significant and currently relevant hematologic, renal, hepatic, gastrointestinal, endocrine, pulmonary, dermatologic, oncologic or neurologic (including seizures or epilepsy) disease
- Patients with a history of or symptoms on systems review consistent with significant cardiovascular disease, bypass surgery, or concurrent cardiovascular disease, including uncontrolled hypertension, hypotension, congestive heart failure, angina pectoris, or recent (within last 6 months) myocardial infarction
- Use of any investigational drug within 4 weeks before screening
- History of hypersensitivity or other intolerable adverse effects to modafinil
- Patients who experience severe sleep disturbances from modafinil
Data sourced from ClinicalTrials.gov (NCT00373672). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.